-
Heavy! The eighth batch of national procurement reporting documents involved 41 varieties and 181 product specifications
Time of Update: 2023-02-01
Appendix 1: Fill in the report of relevant drug procurement demand Appendix 2: The current competitive pattern of the eighth batch of centralized procurement varieties Data sources: NMPA, pharmacointelligence dataPS: The data is manually statistically collated, if there is a missing data, please understand, but also please correct in the comment area, thank you!If this article violates your rights, please contact us.
-
In 2022, the medical device industry will continue to grow rapidly, and the operating income is expected to reach 1.3 trillion yuan
Time of Update: 2023-02-01
Analysts pointed out that benefiting from the development of the economic level, the health demand is increasing, and China's medical device market has ushered in huge development opportunities. Thro
-
In 2023, the pace of mergers and acquisitions by multinational pharmaceutical companies may accelerate, targeting two hundred billion US dollar markets
Time of Update: 2023-02-01
Looking back on 2022, although the popularity of acquisitions in the pharmaceutical industry has decreased compared with the previous year, it is still remarkable. According to the 2022 pharmaceutica
-
Since the implementation of the "Category B and B Management" policy, the number of people entering and leaving the country has recovered in an orderly manner
Time of Update: 2023-02-01
The average daily number of arrivals and exits at seaports, land routes and air ports was 21,000, 424,000 and 45,000 respectively, an increase of 13%, 53.
The average daily number of arrivals and exits at seaports, land routes and air ports was 21,000, 424,000 and 45,000 respectively, an increase of 13%, 53.
-
The era of dental implants is coming to an end? The price of imported brands dropped to more than 100 yuan
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search.
js?cdnversion='+~(-new Date()/36e5)];On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search.
-
In the past week, a large number of pharmaceutical companies have obtained drug registration certificates!
Time of Update: 2023-02-01
News on January 13, Huaren Pharmaceutical said that it recently received the "Drug Registration Certificate" of "sodium bicarbonate Ringer injection" approved and issued by the National Medical Products Administration.
-
Letter soliciting comments on the draft general rules and supporting general testing methods for plastic containers and components for pharmaceutical packaging under the Chinese Pharmacopoeia (first batch).
Time of Update: 2023-02-01
Source: National Pharmacopoeia Commission Time: 2023-01-16 10:43:54 Print Related: According to the work plan, our committee organized and drafted 5 general rules related to plastic containers and components for pharmaceutical packaging and 9 draft supporting general testing methods (see Annex 1-6), and is now soliciting relevant opinions on the draft standard.
-
2022 pharmaceutical company report card: 1 company has disclosed a bright performance report, and more than 10 companies have increased their performance
Time of Update: 2023-02-01
According to the statistics of the data center of Oriental Fortune Network, as of January 11, about 20 pharmaceutical companies in the pharmaceutical industry have released 2022 performance reports and performance forecasts, of which 1 has disclosed bright performance reports, and more than 10 have increased their performance.
-
R&D investment continues to increase, and the modernization of Chinese medicine is accelerating
Time of Update: 2023-02-01
In addition, in recent years, Yiling Pharmaceutical is also making full use of the methods and means of modern science and technology to continuously increase investment in scientific research and leapfrog development of innovative Chinese medicine drugs on the basis of inheriting and carrying forward the advantages and characteristics of traditional Chinese medicine.
-
Recently, there has been good news in the field of anti-tumor drugs, involving clinical and marketing...
Time of Update: 2023-02-01
The company's cyclophosphamide capsules (25mg) were included in the priority review and approval process in October 2021, and the approval of both specifications (25mg and 50mg) is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs.
-
A number of pharmaceutical companies have achieved good results, and Huahai Pharmaceutical's net profit has doubled
Time of Update: 2023-02-01
Jiudian Pharmaceutical also released a performance forecast on the evening of January 15, saying that it is expected that the net profit attributable to shareholders of listed companies in 2022 will be 263 million yuan ~ 273 million yuan, a year-on-year increase of 28.
-
Another batch of pharmaceutical companies announced fundraising projects, mainly focusing on new drug research and development and other fields
Time of Update: 2023-02-01
279 billion yuan after the IPO of Xintong Drug Science and Technology Innovation Board, of which 900 million yuan will be used for new drug research and development projects, 180 million yuan will be used for innovative drug industrialization production base construction projects, and 200 million yuan will be used for supplementary working capital projects.
-
In the past 5 trading days, 120 listed companies have been investigated by institutions! 14 pharmaceutical companies, including Dirui Medical, were investigated
Time of Update: 2023-02-01
Seven pharmaceutical stocks rose, focusing on traditional Chinese medicine, medical devices and other tracks In the secondary market, among the 14 pharmaceutical stocks surveyed by institutions in the past 5 trading days, a total of 7 stocks rose, including Haixiang Pharmaceutical, Winbond Health, Watson Biotechnology, Heavy Drug Holdings, Zhenbao Island, Rhein Biotechnology, Beikang, Dirui Medical, etc.
-
AstraZeneca's $1.8 billion acquisition! Why is Cincor just one year on the market?
Time of Update: 2023-02-01
1It has only been on the market for one yearGet market focus with Baxdrostat Founded in 2018, CinCor is a clinical-stage biopharmaceutical company based in the United States focused on developing novel therapies for refractory and uncontrolled hypertension and chronic kidney disease.
-
Notice on public solicitation of opinions on the "Technical Guidelines for the Research of Improved New Drugs of Traditional Chinese Medicine (Draft for Comments)"
Time of Update: 2023-02-01
Notice on public solicitation of opinions on the "Technical Guidelines for the Research of Improved New Drugs of Traditional Chinese Medicine (Draft for Comments)"Release date: 20230106 According to
-
Affected by the surge in demand for Paxlovid, Pfizer is ready to start production in China
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];A few days ago, Pfizer CEO Aberle said that the surge in demand for Paxlovid in the Chinese market has led to tight supply, and it is working with a Chinese contract drugmaker to prepare for local production.
-
Hundreds of millions of discounted interest loans help mass spectrometer procurement! Last month, the total amount of the mass spectrometer won the bid exceeded 1.1 billion
Time of Update: 2023-02-01
On September 7, 2022, the executive meeting of the State Council decided to impose a 2. 5% financial discount on loans for equipment renovation and renovation in some fields before December 31, and o
-
Since January, the cumulative transaction turnover of the pharmaceutical industry has exceeded 10 billion, and Hengrui has "won the championship"
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Data show that as of January 15, a total of 1,871 large transactions have occurred in the A-share market since 2023, with a cumulative transaction volume of 2.
-
At the beginning of the new year, many pharmaceutical companies have begun to look forward to 2023 performance!
Time of Update: 2023-02-01
. In addition, Guizhou Sanli is expected to achieve a net profit attributable to the owner of the parent company of 196 million yuan ~ 217 million yuan in 2022, an increase of 43.
-
In the "height" market of tens of billions of yuan, the product research and development of many pharmaceutical companies has ushered in new progress
Time of Update: 2023-02-01
Recently, Changchun High-tech issued the "Announcement on the Approval of New Indications of Recombinant Human Growth Hormone Injection of Holding Subsidiaries" (hereinafter referred to as the "Announcement"), and the approved and increased indication of the drug is prepubertal growth disorder caused by chronic kidney disease (CKD).